Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $30.
August 30, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics and maintained a price target of $30, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $30 price target by Needham suggests positive sentiment and confidence in Viridian Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100